tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Melissa Benson

Melissa Benson

Wilsons
Wall Street Analyst
Ranked #5,579 out of 8,014 Analysts on TipRanks (#14,922 out of 21,455 overall experts)

Success Rate

42%
5 out of 12 Profitable Transactions

Average Return

-1.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Melissa Benson's ratings since 2022 and opened each position for the duration of 1 Year:
41.67% of your transactions would have been profitable with an average return of -1.7%

Stock Rating Distribution

16Ratings
81.25% Buy
18.75% Hold
0.00% Sell
Distribution of Melissa Benson's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Mayne Pharma Group Limited
(MAYNF)
Rating Type:Buy
Dates:Apr 05, 2022 - Jan 01, 1970
Gain:36.20%
The most profitable rating made by Melissa Benson

Melissa Benson's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Antisense Therapeutics Limited
Buy
Reiterated
$0.40
(534.26% Upside)
0%
-23.60%
1
Opthea Limited
Buy
Reiterated
$0.76
(-6.86% Downside)
0%
-20.70%
1
Immutep Ltd
Buy
Reiterated
$0.64
(179.84% Upside)
0%
-22.78%
4
Pro Medicus Limited
Buy
Reiterated
$36.06
(-5.44% Downside)
100%
+28.20%
2
Clinuvel Pharmaceuticals Limited
Buy
Reiterated
$17.25
(31.81% Upside)
67%
+14.70%
6
Mayne Pharma Group Limited
Buy
Reiterated
$0.23
(-11.76% Downside)
100%
+20.80%
2
List of latest recommendations made by Melissa Benson. Click to expand and see Melissa Benson's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More